187 related articles for article (PubMed ID: 29544370)
1. Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.
Piro G; Carbone C; Santoro R; Tortora G; Melisi D
Expert Rev Mol Diagn; 2018 Apr; 18(4):357-370. PubMed ID: 29544370
[TBL] [Abstract][Full Text] [Related]
2. Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma.
Fong CY; Chau I
Pharmacogenomics; 2021 Jul; 22(11):703-726. PubMed ID: 34120461
[TBL] [Abstract][Full Text] [Related]
3. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches.
Davidson M; Chau I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):327-338. PubMed ID: 29431018
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of the esophago-gastric junction adenocarcinoma].
Bîrlă R; Losif C; Gîndea C; Hoară P; Constantinoiu S
Chirurgia (Bucur); 2008; 103(2):143-53. PubMed ID: 18457092
[TBL] [Abstract][Full Text] [Related]
5. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
Sandler S
Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
[TBL] [Abstract][Full Text] [Related]
6. Treatment approaches to esophagogastric junction tumors.
Kurokawa Y; Sasako M; Doki Y
Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
[TBL] [Abstract][Full Text] [Related]
7. Cancer of the gastroesophageal junction: combined modality therapy.
Ilson DH
Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
Bibby BA; Reynolds JV; Maher SG
PLoS One; 2015; 10(7):e0134180. PubMed ID: 26221725
[TBL] [Abstract][Full Text] [Related]
9. Oesophagogastric junction adenocarcinoma: which therapeutic approach?
Mariette C; Piessen G; Briez N; Gronnier C; Triboulet JP
Lancet Oncol; 2011 Mar; 12(3):296-305. PubMed ID: 21109491
[TBL] [Abstract][Full Text] [Related]
10. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
[TBL] [Abstract][Full Text] [Related]
11. Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction.
Odenthal M; Hee J; Gockel I; Sisic L; Schmitz J; Stoecklein NH; Driemel C; Möhlendick B; Schmidt T; Knoefel WT; Lang H; Büttner R; Ott K; Vallböhmer D
Int J Cancer; 2015 Jul; 137(1):230-7. PubMed ID: 25429911
[TBL] [Abstract][Full Text] [Related]
12. [Multimodality therapy for adenocarcinoma of the esophagogastric junction].
He J; Huang JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Sep; 15(9):877-80. PubMed ID: 22990915
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma.
Lau DK; Athauda A; Chau I
Expert Opin Pharmacother; 2021 Aug; 22(11):1429-1441. PubMed ID: 33688789
[No Abstract] [Full Text] [Related]
14. Emerging therapeutic targets in esophageal adenocarcinoma.
Gaur P; Hunt CR; Pandita TK
Oncotarget; 2016 Jul; 7(30):48644-48655. PubMed ID: 27102294
[TBL] [Abstract][Full Text] [Related]
15. [Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction].
Ben Salah H; Bahri M; Dhouib F; Daoud J
Cancer Radiother; 2016 Dec; 20(8):830-832. PubMed ID: 27793531
[TBL] [Abstract][Full Text] [Related]
16. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
[TBL] [Abstract][Full Text] [Related]
17. Recurrence after surgery in esophago-gastric junction adenocarcinoma: Current management and future perspectives.
Neri A; Marrelli D; Voglino C; Di Mare G; Ferrara F; Marini M; Roviello F
Surg Oncol; 2016 Dec; 25(4):355-363. PubMed ID: 27916166
[TBL] [Abstract][Full Text] [Related]
18. Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?
Cartwright E; Keane FK; Enzinger PC; Hong T; Chau I
Am Soc Clin Oncol Educ Book; 2018 May; 38():280-291. PubMed ID: 30231360
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic approaches to gastroesophageal junction adenocarcinomas.
Blom RL; Bogush T; Brücher BL; Chang AC; Davydov M; Dudko E; Leong T; Polotsky B; Swanson PE; van Rossum PS; Ruurda JP; Sagaert X; Tjulandin S; Schraepen MC; Sosef MN; van Hillegersberg R
Ann N Y Acad Sci; 2014 Sep; 1325():197-210. PubMed ID: 25266026
[TBL] [Abstract][Full Text] [Related]
20. Superior socio-medical alternative to feeding gastrostomy and jejunostomy in advanced esophago-gastric junction adenocarcinoma.
Hulpuş R; Constantinoiu S; Bratu D; Dumitra A; Sabău A; Sabău D; Ursache E; Negreanu L; Smarandache CG
Chirurgia (Bucur); 2013; 108(4):451-5. PubMed ID: 23958084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
